Dyspnea Treatment Market to reach USD 11.01 Billion by 2032, and grow at a CAGR of 6.95%
The high burden of cardiopulmonary diseases, increase in population-based overweight, and lifestyle changes are responsible for having dyspnea. The February 2022 article in the European Respiratory Journal titled \"Prevalence and severity of different dimensions of breathlessness among the population: A systematic review, meta-analysis \" notes that for decades dyspnea has been a clinical symptom suffered by patients with cardiorespiratory disease (cardiopulmonary), as well as prevalent within community-based populations. 10-25% of middle-aged to older adults become short of breath performing normal activities. Hence, the rise in the prevalence of dyspnea is expected to increase its management and treatment due to avoidable disciplines that would drive overall market growth.